KURA
Kura Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.26
−2.84%Year over year
Reported trailing growth
- Revenue
- -7.3%
- EBITDA
- -52.3%
- EBIT
- -44.8%
- EPS
- -49.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +122.0%
- EBITDA
- +20.2%
- EPS
- +20.6%
Three-year CAGR
- Revenue
- +25.2%
- EBITDA
- -62.7%
- EBIT
- -57.2%
- Net income
- -60.2%
- EPS
- -57.4%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026